Posted by Michael Wonder on 04 Mar 2025
ICER publishes special report on COPD therapies as part of CMS public comment process on Medicare drug price negotiations
3 March 2025 - Report reflects legislative specifications in the Inflation Reduction Act and subsequent CMS guidance.
The ICER today posted a special report evaluating the evidence of two chronic obstructive pulmonary disease treatments, Trelegy Ellipta and Breo Ellipta, that will be sent as its public comment submission to Centers for Medicare & Medicaid Services as part of its work on Medicare drug price negotiations.
